Trial · NCT07895732
Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma
NCT07895732, Phase 3, Not yet recruiting, University Health Network, Toronto
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma. Trials, record NCT07895732. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895732
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma
- NCT number
- NCT07895732
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 60 participants, estimated
- Lead sponsor
- University Health Network, Toronto
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Best Supportive Care (BSC), Personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR)
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) | 5 years | Overall survival (OS) is defined as the time from randomization to death from any cause. OS will be estimated using the Kaplan-Meier method and compared between both arms using a log-rank test. |
| Secondary | Progression Free Survival (PFS) | From randomization until disease progression, death, or end of follow-up (up to [5 years]). | Progressive-free survival (PFS): time to progression or death |
| Secondary | Lesion Progression | 5 years | Progression and/or development of new (intrahepatic or extra-hepatic) lesions are defined by RECIST 1.1 criteria after comprehensive clinical examination and radiographic evaluation. |
| Secondary | Liver Decompensation (Child Pugh) | 5 years | Assessed using Child Pugh score where higher scores indicating worse liver function. |
| Secondary | Liver Decompensation (mALBI) | 5 years | Modified ALBI (mALBI) score where it ranges from Grade 1 (best liver function) to Grade 3 (worst liver function). |
| Secondary | Physician-assessed toxicities | 5 years | National Cancer Institute (NCI) Common Terminology Criteria of Adverse Events (CTCAE) V.6 where higher grades indicate greater severity of toxicity. |
| Secondary | Patients-reported toxicities | 5 years | Patient Reported Outcomes - Common Terminology Criteria of Adverse Events (PRO CTCAE) V.1 where higher scores indicate greater symptom burden and worse patient-reported toxicity. |
| Secondary | Quality of life (QOL) (FACT-Hep) | 5 years | Functional Assessment of Cancer Therapy - Hepatobiliary (FACT-Hep), with higher scores indicating better health-related quality of life. |
| Secondary | Quality of life (QOL) (EQ-5D-5L) | 5 years | EQ-5D-5L questionnaires, where higher scores indicate better health-related quality of life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895732
GET https://conductscience.org/api/trials/v1/NCT07895732/registered